Get started
Author

Robert Godal

Observed name: R. Godal
OpenAlex ID: A5048648514
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688
Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptor–Negative Natural Killer Cells after NKG2A and LIR-1 Blockade
2010 · Robert Godal, Veronika Bachanova, et al. · Transplantation and Cellular Therapy · 97
Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2
2005 · Robert Godal, Ulrich Keilholz, et al. · Blood · 39
Blocking Inhibitory KIR Is Insufficient for Optimal Killing of AML and ALL Targets: Additional Requirements for NKG2A and LIR-1 Blockade
2008 · Robert Godal, Michelle Gleason, et al. · Blood · 1
Lymphoma Cells Are Highly Sensitive to Cytotoxic T-Cell-Killing Despite Presence of Multiple Resistance Mechanisms
2004 · Robert Godal, Carmen Scheibenbogen, et al. · Journal of Immunotherapy · 1
EP1.04-19 First Experience with Atezolizumab in Slovakia
2019 · P. Kasan, P. Berzinec, et al. · Journal of Thoracic Oncology
PDF
P2.03-056 Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 in Slovakiab NSCLC Patients - Updated Survival Data
2017 · P. Berzinec, P. Kasan, et al. · Journal of Thoracic Oncology
P3.02a-026 Crizotinib in Clinical Practice and in Clinical Trials - How Much the Results Differ?
2017 · Peter Berzinec, Lukas Plank, et al. · Journal of Thoracic Oncology
PDF
P3.02b-029 Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 - Prevalence and Treatment Results in Slovakian NSCLC Patients
2017 · Peter Berzinec, Lukas Plank, et al. · Journal of Thoracic Oncology
P15. Crizotinib in metastatic ALK-positive lung cancer—results from clinical practice in Slovakia
2014 · Peter Berzinec, Peter Kasan, et al. · Europe PMC (PubMed Central)
Killer Immunoglobulin Receptor (KIR) Negative NK Cells Exhibit Potent Alloreactivity Against Primary Leukemia Targets When Interrupting MHC Class I Interactions through NKG2A Blockade.
2007 · Robert Godal, Michelle Gleason, et al. · Blood
Works count: 12
Citation count: 3,104
H-index: 4
I10-index: 4
Year
Topic
Type